Date: 2011-09-15
Type of information: Fundraising
Company: Cellectis (France)
Investors: FSI (France) - private investor Pierre Bastide
Amount: €50 million
Funding type: fundraising
Planned used: This fundraising will be used to finance the cash component of the acquisition of Cellartis and to accelerate the development of its other businesses.
Others: Cellectis will raise €50 million from the FSI and Pierre Bastid. This financing will be carried out by the Board of Directors, upon delegation of the shareholders’ general meeting:
- either through a reserved capital increase, if Cellectis share price is greater than €8 (in which case the issuing price will be comprised between €8 and €9);
- or through a reserved issue of bonds redeemable into shares (“ORAs”) if the share price is inferior to €8. In this case, the ORAs would be issued at €8.
Cellectis would therefore acquire the financial resources to secure its mid-term development, and a stable shareholder base, which are two strong assets for the group’s development.
Furthermore, the Board of Directors will be expanded to eight members and two observers, including two directors appointed upon proposal by the FSI and one director and one observer appointed upon proposal by Pierre Bastid.
Therapeutic area: Technology - Services
